InflaRx NV
NASDAQ:IFRX

Watchlist Manager
InflaRx NV Logo
InflaRx NV
NASDAQ:IFRX
Watchlist
Price: 1.11 USD 4.72% Market Closed
Market Cap: 74.5m USD

Operating Margin
InflaRx NV

-71 348.5%
Current
-33 994%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-71 348.5%
=
Operating Profit
-45.2m
/
Revenue
63.3k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DE
InflaRx NV
NASDAQ:IFRX
75.2m USD
-71 349%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
400.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD
28%
AU
CSL Ltd
ASX:CSL
85.6B AUD
26%
NL
argenx SE
XBRU:ARGX
44.8B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
No Stocks Found

InflaRx NV
Glance View

Market Cap
75.2m USD
Industry
Biotechnology

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

IFRX Intrinsic Value
0.26 USD
Overvaluation 76%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-71 348.5%
=
Operating Profit
-45.2m
/
Revenue
63.3k
What is the Operating Margin of InflaRx NV?

Based on InflaRx NV's most recent financial statements, the company has Operating Margin of -71 348.5%.

Back to Top